Advertisement

Apollo Endosurgery closes the books on its acquisition of Allergan's obesity intervention business, including the Lap-Band and Orbera technologies, in a deal worth up to $110 million.

Allergan finalizes Lap-Band division sale

Medtech company Allergan (NYSE:AGN) officially dumped its obesity interventions business, consummating with Apollo Endosurgery a deal worth up to $110 million.

The transaction provides Allergan with up-front cash of $75 million in addition to a $15 million minority interest in Apollo and $20 million in regulatory and sales milestones, according to an Apollo statement.

Advertisement
Advertisement